These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 8694659)

  • 21. [Guideline 'NSAID use and the prevention of gastric damage'].
    Moens HJ; van Croonenborg JJ; Al MJ; van den Bemt PM; Lourens J; Numans ME;
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):604-8. PubMed ID: 15083624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NSAID association with gastrointestinal bleeding and peptic ulcer.
    Hirschowitz BI; Lanas A
    Agents Actions Suppl; 1991; 35():93-101. PubMed ID: 1781426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs.
    Vakil N
    Rev Gastroenterol Disord; 2006; 6(4):221-6. PubMed ID: 17224894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
    McCarthy DM
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis.
    Keenan GF; Giannini EH; Athreya BH
    J Rheumatol; 1995 Jun; 22(6):1149-51. PubMed ID: 7674245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations.
    Stucki G; Johannesson M; Liang MH
    Arch Intern Med; 1994 Sep; 154(18):2020-5. PubMed ID: 8092907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
    Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
    Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
    Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Steen KS; Lems WF; Dijkmans BA
    Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1649-52. PubMed ID: 10494299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NSAID and gastropathy: a rheumatologist's review.
    Roth SH
    J Rheumatol; 1988 Jun; 15(6):912-9. PubMed ID: 3047383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specifics of Helicobacter pylori infection/NSAID effects in the elderly.
    Davidovic M; Svorcan P; Milanovic P; Antovic A; Milosevic D
    Rom J Gastroenterol; 2005 Sep; 14(3):253-8. PubMed ID: 16200236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostaglandins, NSAIDs, and cytoprotection.
    Wallace JL
    Gastroenterol Clin North Am; 1992 Sep; 21(3):631-41. PubMed ID: 1516961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?
    Adebayo D; Bjarnason I
    Postgrad Med J; 2006 Mar; 82(965):186-91. PubMed ID: 16517800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response.
    Roth SH; Bennett RE
    Arch Intern Med; 1987 Dec; 147(12):2093-100. PubMed ID: 3318750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.